Introduction: Incidence rates of colorectal cancer in the Orenburg Region exceed the national averages, thus highlighting the importance of early diagnosis. In 2022, a pilot screening project was implemented in the region, and its results served as the basis for expanding the coverage throughout the region. Objective: To determine the list of indicators for the high-quality implementation of colorectal cancer screening and their target levels based on the results of the pilot project. Materials and Methods: The colorectal cancer screening pilot project lasted six months and involved 3,278 participants aged 40 and above, all working at large enterprises of the Orenburg Region. The screening process included a fecal occult blood test (FOBT) at stage 1 and, if needed, colonoscopy at stage 2. During the pilot project, indicators were evaluated according to a predefined list (the proportion of positive FOB test results, endoscopy coverage, the proportion of colonoscopies with debridement/total polypectomy (in outpatient settings), and the proportion of colonoscopies with biopsy). Target levels and the final list were established based on the distribution of the findings. Results: At the laboratory stage, 10.3 % of all participants had a positive FOBT result and 81.3 % of them underwent endoscopic examination. Of 273 colonoscopies performed, 42 % resulted in complete debridement and 11 % were performed with biopsy; intestinal pathology was detected in 61.9 % of them, including polyps and six cancer cases, with the adenoma and cancer detection rates of 26 % and 0.18 %, respectively. These metrics, including the percentage of positive test results, endoscopy coverage, and the level of outpatient polypectomies, will facilitate the evaluation of screening quality and effectiveness and decision making for the long-term reduction in colorectal cancer incidence and mortality rates. Conclusions: The pilot project implemented in the Orenburg Region confirmed the effectiveness of a two-stage screening strategy based on quantitative fecal analysis and colonoscopy, with the identification of key indicators that will ensure the control and monitoring of the program at the regional level.
Background. A Russian phase IV observational study was initiated to evaluate the efficacy and safety of lenvatinib with pembrolizumab (Len-Pembro) in patients with advanced renal cell carcinoma (RCC) receiving therapy in real-world practice. This article is based on the results of the third analysis conducted with a median follow-up of 23.1 months and reflects data on the efficacy and safety of Len-Pembro in Russian patients. Aim. To evaluate the real-world efficacy and safety of Len-Pembro in patients with advanced RCC with a median follow-up increased to 23.1 months. The primary outcome of the study was progression-free survival (PFS), the secondary outcomes included overall survival (OS), progression-free survival on next-line therapy (PFS2), objective response rate (ORR), duration of response, as well as safety. Materials and methods. The study included data from 165 patients with verified advanced RCC who received Len-Pembro at 36 centers in the Russian Federation from February 05, 2018 to July 30, 2025. The median age was 60 (20–76) years, and 70.3% of the participants were male. Most patients (74.6%) presented with Karnofsky performance score of ≥80%, metachronous metastases (50.9%) of clear cell RCC (93.3%) in 1 organ (75.2%), and had not received any anticancer treatment (91.0%). The IMDC favorable prognosis group included 40 (24.2%), intermediate – 92 (55.8%), and unfavorable prognosis – 33 (20.0%) patients. The median follow-up reached 23.1 (0.5–72.9) months. A total of 110 (66.7%) patients completed Len-Pembro therapy, and 51 (30.9%) patients received next-line treatment. Results. Median PFS reached 25.8 (95% confidence interval – CI 17.0–34.5) months, 23-month PFS – 52.6%; median OS was 39.9 (95% CI 26.9–52.8) months, 23-month OS – 73.1%; median PFS2 was 33.2 (95% CI 23.4–41.1) months, 23-month PFS2 – 66.9%. The ORR was 49.1%, including 3.0% of complete responses, and the disease control rate was 89.1%. The median duration of response reached 29.7 (95% CI 24.9–34.6) months. The incidence of any adverse events (AEs) was 78.8%, severe AEs occurred in 29.1%, fatal AES – in 1.2%, immune-related AEs – 17.0%, severe immune-related AEs – 6.7%. Conclusion. In real-world practice, with increased follow-up duration, the values of PFS, OS, and PFS2 were comparable to those obtained in the registrational study, with a lower ORR and a satisfactory safety profile of the combination of Len-Pembro in advanced RCC.
В данном разделе указаны критерии оценки клинической значимости применения дорогостоящей противоопухолевой лекарственной терапии в соответствии со шкалой, разработанной экспертной группой (см. стр. 7). В тексте они обозначены, как магнитуда клинической значимости (МКЗ).
Objective. Aim of the article is the analysis and generalisation of the experience on the joint scientific-practical activity of the anatomic-surgical department of medical university and clinical oncology dispensary. Results. There is present the experience of joint working of microsurgical operative interventions, alive clinical anatomy of organs, topographic-anatomical changes in body cavities after radical surgery operations. There is show the significance of the joint activity for the department of operative surgery and clinical anatomy Orenburg State Medical University and Orenburg Regional Clinical Oncology Dispensary. Conclusion. The experience of scientific-practical community evidences about effectiveness and of utility joint scientific work of medical university department and medical hospital.
В данном разделе указаны критерии оценки клинической значимости применения дорогостоящей противоопухолевой лекарственной терапии в соответствии со шкалой, разработанной экспертной группой (см. стр. 7). В тексте они обозначены, как магнитуда клинической значимости (МКЗ).
